高血压是一种常见病,降压治疗是一个永恒的话题。看似简单的一种疾病,却依然存在太多未知。正因如此,近年来与降压治疗有关的争议性话题不断。在降压治疗领域,2015年有以下几点值得关注。1β受体阻滞剂在降压治疗中的地位近年来,围绕β受体阻滞剂是否应继续作为一线降压药物的争论从未中断。但在很多文章或专家讲座中,这一争论时常被有意无意地偷换概念。无论英国、美国、日本还是加拿大指南,认为β受体阻滞剂不适于 Hypertension is a common disease, antihypertensive treatment is an eternal topic. A seemingly simple disease, but there are still too many unknown. Because of this, the controversial topics related to antihypertensive treatment have continued in recent years. In the field of antihypertensive treatment, the following points in 2015 are noteworthy. The Role of 1β-Receptor Blockers in Antihypertensive Therapy The debate over whether beta blockers should continue as first-line antihypertensive agents in recent years has never ceased. However, in many articles or expert lectures, this controversy is often deliberately or inadvertently replaced concept. Regardless of the United Kingdom, the United States, Japan or Canada guidelines, that β-blockers are not suitable